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Abstract
This is a review article on adjuvants to neuroaxial anaesthesia and peri-
pheral nerve blocks used in clinical practice: opioids, vasoconstrictors,
clonidine, NMDA antagonists, midazolam, glucocorticoids, nonsteroidal
anti-inflammatory drugs and neostigmine. Mechanisam and site of action
of each of them is described. It is followed by discussion of experimental and
clinical data published in the last five years.
INTRODUCTION
The suggestion that regionally applied opioids might be effective asanalgesics dates back to the mid nineteen’s century when mor-
phine was injected perineurally. For many years to come, the site of ac-
tion of opioids was thought to be in the brain only. The first report on
opioids for intrathecal anaesthesia was published in 1901 and on epi-
dural morphine in 1979 (1). The existence of specific opioid receptors
in the spinal cord and a segmental distribution of opioid analgesia were
reported in the 70’ies. In addition to the direct spinal action, morphine
conveys descending pathway inhibition by its influence on the peri-
aqueductal grey matter and rostral ventromedial medulla (2). Analge-
sia produced by neuraxial opioids alone, or as adjuvants to local anaes-
thetics, has been demonstrated for acute postoperative pain, obstetric,
paediatric, and cancer pain (3).
Besides morphine a number of different opioides and other adju-
vants have been introduced to improve the efficacy of neuraxial/regio-
nal analgesia, including NMDA antagonists (ketamine, magnesium),
GABA agonists (midazolam) and adrenergic agonists (clonidine, adre-
naline), COX-inhibitors (ketorolac), Ach-esterase inhibitor (neostig-
mine) etc. (4). This review is based on articles published during the last
five years.
OPIOID ADJUVANTS
Mechanism of opioid action and receptor types
Afferent noxious stimuli converge in the dorsal horn of the spinal
cord, where the primary nociceptive neuron synapses with the wide dy-
namic range interneurons and the second order nociceptive neuron in
the spinothalamic tract. Agonism of these opioid receptors helps to sup-
press afferent nociceptive input from pain sites via modulation of the
release of pain-pathway associated peptides (5).
Opioids produce analgesia by mimicking the actions at specific re-
ceptors of endogenous opioid peptides, including metenkephalin, beta-
-endorphin, and dynorphin. The three main types of opiate receptors,
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each with its own subtypes, are mu (m), delta (d), and
kappa (k) (6). The most important target for opioids is
the m-receptor (endorphin), and intrathecal opioids ap-
pear to selectively modulate C- and A-fibres with mini-
mal impact on dorsal root axons. The enkephalins are
the primary endogenous ligands of the d receptor and are
involved with spinal analgesia. Dynorphin is the proto-
typic ligand for the k receptor. Activation of the k recep-
tor results in segmental spinal analgesia and sedation.
Most of the mixed agonist- antagonist opioids (e.g., bu-
torphanol) bind to the k receptor.
Any drug given intrathecally rapidly redistributes with-
in the CSF; opioid is detectable in the cisterna magna af-
ter lumbar intrathecal administration within 30 min,
even with lipophilic drugs like sufentanil.
The lipophilic opioids rapidly traverse the dura where
they are sequestered in the epidural fat and enter the sys-
temic circulation; they also rapidly penetrate the spinal
cord where they bind to both non-specific sites within the
white matter as well as dorsal horn receptors and eventu-
ally enter the systemic circulation as they are cleared
from the spinal cord. This rapid transfer from the CSF to
both spinal cord and the epidural fat explains the rapid
onset and the prompt decline in CSF levels of lipophilic
opioid, accounting for the minimal rostral spread, lack of
delayed respiratory depression, and relatively small der-
matomal band of analgesia seen during chronic adminis-
tration (7).
Morphine, the prototypic hydrophilic opioid, under-
goes a similar transfer to both the spinal cord and the
epidural space; however, there is limited binding to fat
within the epidural space and limited binding to nonspe-
cific receptors within the spinal cord white matter. Trans-
fer to the systemic circulation is likewise slower than for
the lipophilic drugs (8).
Cephalad spread
Despite decades of use, controversy remains regard-
ing the extent and time course of the cephalad spread of
opioids in cerebrospinal fluid (CSF) after intrathecal in-
jection. Eight healthy volunteers received intrathecal in-
jection of morphine plus fentanyl at a lower lumbar
interspace (9). CSF was sampled through a needle in an
upper lumbar interspace for 60–120 min. At the end of
this time, a sample was taken from the lower lumbar nee-
dle, and both needles were withdrawn. Fentanyl was
found to be more rapidly cleared from CSF than mor-
phine, although their initial distribution in the first hour
after injection did not differ greatly. The pharmacokine-
tic model demonstrates that mixing is the primary deter-
minant of early concentrations and is highly variable
among individuals. Morphine moved cephalad with si-
milar rapidity to fentanyl in this study, and its slow onset
for analgesia presumably reflects slow penetration into
spinal cord tissue rather than major differences in move-
ment in CSF (9).
Site of action
In a study by Bernards the residence time of hydro-
phobic opioids in the epidural space was prolonged (10).
This is consistent with the findings in multiple human
studies having shown that epidurally administered alfen-
tanil, sufentanil, and fentanyl produce little, if any, of their
postoperative analgesic effects via a spinal mechanism.
They have negligible access to the spinal cord because of
sequestration and/or rapid vascular uptake from the epi-
dural space. Epidural pharmacokinetics did not predict
CSF pharmacokinetics. The reason(s) behind this appar-
ent dissociation is unclear. It may be that the opioids accu-
mulate to varying degrees in intervening barriers (e.g.,
dura mater, arachnoid mater, epidural fat) and that their
CSF pharmacokinetics are dependent on their pharmaco-
kinetics in these tissues as much as on their pharmaco-
kinetics in the extracellular fluid of the epidural space.
The study confirmed that after epidural administration,
morphine has much greater bioavailability in the spinal
cord than alfentanil, fentanyl, and sufentanil (10).
Site of action and bolus vs infusion
Most published studies suggesting that epidural fent-
anyl acts predominantly at spinal sites administered the
drug as a bolus injection, whereas most studies suggesting
that it acts predominantly at supraspinal sites administer-
ed the drug as an infusion. Ginosar tested the hypothesis
that the mode of administration (bolus versus infusion)
of epidural fentanyl determines its site of action (11).
Ten healthy volunteers were enrolled in this random-
ized, double-blinded, cross-over study. On separate study
days, fentanyl was administered into the epidural space
as a bolus and as an infusion. Using a thermal and elec-
trical experimental pain model, the heat and electrical
current causing maximum tolerable pain were assessed
repetitively. Plasma fentanyl concentrations were deter-
mined throughout the study. Epidural bolus administra-
tion of fentanyl resulted in segmental analgesia, whereas
the epidural infusion of fentanyl produced nonsegmental
analgesia. There was a significant linear relationship be-
tween the analgesic effect and the plasma concentration
of fentanyl for the epidural infusion but not for the
epidural bolus administration of fentanyl. Bolus admin-
istration resulted in significant segmental analgesic ef-
fects, whereas the infusion produced significant systemic
analgesic effects. These findings might explain the ap-
parent conflict in the literature regarding the site of ac-
tion of epidural fentanyl (11).
Even if this study indicates that epidural fentanyl acts
predominantly at spinal sites if administered as a bolus
and at supraspinal sites if administered as an infusion,
there are pharmacokinetic concerns (8). In an editorial,
the fact that plasma concentrations corresponded with
the analgesic effect of infusion but not bolus administra-
tion was called into question. The central argument that
the editors present is that, given larger bolus doses, more
fentanyl is likely to be distributed into the fatty tissues
and be subsequently absorbed systemically. However,
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larger bolus doses were not tested in the study and the
dose administered in this manner was three times less
than that administered by infusion (8). The editors pos-
tulated that, had bolus doses reached those of the infu-
sion, the same linear pattern between plasma concentra-
tion and analgesia would emerge.
Ginosar's paper does not exclude the 'dual sites' the-
ory, which suggests that epidurally administrated opioids
act both spinally and supraspinally with a reinforcing ac-
tion, as this phenomenon would only become apparent
when higher doses are used (11). Ginosar et al. suggest
that the concentration gradient between the epidural and
the intrathecal space is much larger after bolus adminis-
tration than during an infusion, and that with a larger
gradient more fentanyl is likely to be driven into the
intrathecal space and thus reach the dorsal horn in suffi-
cient quantities to elicit spinal analgesia. Large gradients
are not generated during continuous infusion and thus
the drug is redistributed to the systemic circulation. Al-
though no studies appear to have investigated the amount
of opioid required to set up a sufficient gradient, a thresh-
old concentration of 10 mg/ml has been suggested. If an
epidural opioid is administered via an infusion, and the
concentration fails to equal or exceed this 10 mg/ml, then
it is most likely that the opioid is producing analgesia via
a supraspinal mechanism. Given that the vast majority of
postoperative epidural regimes employ low-concentra-
tion infusions, it appears that these regimens are not ca-
pable of producing spinally mediated analgesia (8).
Spinal opioids and local anaesthetics in
synergy
Spinal opioids and local anaesthetics have been shown
to act synergistically at the spinal level in animal studies
(12). Joris therefore tested the hypothesis that sufentanil
requirements will be less when given epidurally than IV
in patients simultaneously given epidural bupivacaine
after major abdominal surgery. In a randomized, dou-
ble-blinded fashion, the sufentanil was given either epi-
durally or IV. Pain scores, extension of sensory block, and
the incidence of side effects did not differ between the
two groups, but consumption of sufentanil in the epi-
dural group was half that of the IV group. It was conclud-
ed that spinal mechanisms contribute to the analgesia
produced by epidural sufentanil in combination with a
local anaesthetic (12).
The advantage of combining the two types of agents
in this manner is thought to be explained by their differ-
ent analgesic properties and their ability to block pain at
two different sites. Opioids produce analgesia by specifi-
cally binding and activating the opiate receptors in the
substantia gelatinosa, whereas local anaesthetics provide
analgesia by blocking impulse transmission at the nerve
roots and dorsal root ganglia. When lipophilic opioids
are injected into the epidural space as a bolus their sys-
temic absorption pattern is biphasic. The initial 'portion'
of the dose is absorbed relatively rapidly into the blood
stream and quickly reaches the supraspinal centres,
whereas the remaining 'portion;' is initially distributed
into the fatty tissues in the epidural space and is then ab-
sorbed into the blood stream more slowly, typically over
the course of several hours. In the absence of a plausible
physiological explanation for synergistic action, it seems
far more likely that the local anaesthetic provides a degree
of spinal, segmental analgesia while, simultaneously, the
opioid is systemically absorbed and provides additional
analgesia supraspinally (8).
Summary of neuraxial opioid
pharmacokinetics
The two tables contain data extracted from the litera-
ture regarding pharmacokinetic properties and dose rec-
ommendations for acute non-malignant pain treatment:
Synergistic interactions between
a2-adrenergic and opioid receptors
Both a2-adrenergic and opioid receptors (a2ARs and
ORs) mediate diverse physiological functions, including
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TABLE 1
Epidural opioid analgesia regimens – Compiled data from the literature.
Opioid Lipid Solubility Dose range Onset (min) Duration (hrs) Continuous Infusion
Morphine ~1 1–5 mg 30–60 12–24 0.1–1 mg/hr
Fentanyl ~800 50–100 mg 5–10 2–4 10–50 mg/hr
Sufentanil ~1800 10–30 mg 5 2–3 2–10 mg/hr
TABLE 2
Intrathecal opioid analgesia regimens – Compiled data from the literature.
Opioid IV/IT Ratio Dose range Onset (min) Duration (hrs) Continuous Infusion
Morphine 2–300:1 0.1–0.5 mg 30 18–24 ?
Fentanyl 10–20:1 5–25 mg 5 1–4 5–20 mg/hr
Sufentanil 10–20:1 2–10 mg 5 2–6 1–5 mg/hr
analgesia. Several reports have described enhanced opi-
ate-mediated spinal antinociception following co-admi-
nistration of low doses of a2AR agonists (13). Furthermore,
it has been shown extensively through both behavioural
and electrophysiological methods that co-activation of
a2ARs and ORs produces synergistic interactions in the
spinal cord. The mechanisms underlying this phenome-
non have yet to be characterized. These aspects of anal-
gesia may be important in managing chronic, opioid-in-
sensitive pain because synergy-enabled decreases in dose
may mitigate the unwanted side effects observed clini-
cally (14).
Experimental data
It has been shown that both morphine and fentanyl
have direct spinal action (15). In a recent study, Good-
child investigated the spinal cord actions of morphine
given intrathecally to rats in a model that allows defini-
tion of drug action at the spinal cord level. This model
has been used previously to show that fentanyl, a selective
m-opioid agonist, can cause antinociception after intra-
thecal injection by actions at spinal cord m-opioid receptors
(15). The opioid receptors were investigated by giving
intrathecal antagonists selective for receptor sub-types at
doses that produced 100% suppression of spinally medi-
ated antinociception caused by drug actions at those re-
ceptors. The authors concluded that the antinociceptive
effects following intrathecal morphine involve spinal
and supraspinal opioid receptors. They also pointed out
that the tail flick effect, frequently described in experi-
ments with morphine administration to rats with an in-
tact neuraxis, involves actions at opioid receptors in the
brain that override any action that may be caused by
combination of morphine with m-opioid receptors in the
spinal cord. This observation can be useful when inter-
preting other studies as well.
An experimental study by Chen provides new func-
tional evidence that systemic morphine inhibits dorsal
horn projection neurons through direct activation of spi-
nal m opioid receptors (16). Their data suggest that inhibi-
tion of spinal dorsal horn neurons, by activation of the lo-
cal spinal cholinergic circuitry after systemic morphine,
is independent of supraspinal descending pathways.
This new information can prove important for our un-
derstanding of the role of spinal m opioid receptors and
cholinergic system in the analgesic action of systemic
opioids. A study by Yamada demonstrated that morphine
could produce thermal antinociception via the kappa
opioid receptor in the spinal cord in the absence of the
mu opioid receptor (17). The finding that the kappa re-
ceptor is a molecular target of morphine at higher doses
suggests that the kappa receptor may play a role in the
analgesia of high-dose morphine regimens used in can-
cer pain treatment.
It is possible that systemic morphine-induced increa-
se in serotonin level in spinal cord activate 5-HT7 receptors
localized on inhibitory enkephalinergic or GABAergic
interneurons that then evoke the release of enkephaline
or GABA. This may then in turn inhibit nociceptive
transmission at sites either presynaptic or postsynaptic to
the terminals of primary afferent fibers. The results of a
recent study by Dogrul support the notion that systemi-
cally administered morphine activate the descending
serotonergic pathways, and that 5-HT7 receptors in the




Fear of uncontrolled postsurgical pain is a major con-
cern of patients undergoing surgery. Another concern is
the more recent documentation of hyperalgesia with very
high opioid doses. In some patients, even short-term
opioid use may lead to opioid-induced hyperalgesia. Di-
stinguishing between this condition and pharmacologi-
cal tolerance has significant implications for managing
postoperative pain (19). Sakurada reviews the potential
mechanisms of spinally mediated nociceptive behaviour
evoked by intrathecal morphine at high concentrations.
The mechanism of action is still unclear but an intra-
thecal administration of morphine in a high concentra-
tion results in an increased release of substance P and
glutamate from the primary afferents in the dorsal horn
of the spinal cord (20). The increased levels of neuro-
transmitters could activate NK1 and NMDA receptors in
the post-synaptic neurons. Morphine-3-glucuronide has
also shown to act as a functional antagonist of the anti-
nociceptive activities of morphine and morphine-6-glu-
curonide. It is therefore plausible that allodynia and
hyperalgesia evoked by spinal morphine at a high con-
centration may result from an increasing accumulation
of morphine-3-glucuronide in the spinal cord.
Peripheral mechanisms of pain and
analgesia
In the late 1980s evidence began to accumulate that
the antinociceptive effects of opioids can be mediated by
peripheral opioid receptors located on sensory neurons
(13). Several studies indicate that a substantial propor-
tion of the analgesic effects produced by systemically ad-
ministered opioids can be mediated by peripheral opioid
receptors (17, 21, 22, 23). In addition, human studies in-
dicate that opioid agonists that do not readily cross the
blood-brain barrier are beneficial in patients with vis-
ceral and neuropathic pain and can have the same anal-
gesic efficacy as conventional opioids. Thus, the analge-
sic efficacy of peripherally active opioids may be utilized
under conditions of acute and chronic pain with the ben-
efit of reduced side effects.
Research in the last three decades has proven the ex-
istence of opioid and other receptors for excitatory and
inhibitory peptides at afferent nerve terminals in periph-
eral tissues (3). The complex interaction of these recep-
tors with endogenous and exogenous compounds, in-
flammatory and immune responses, and sympathetic
nerve endings continues to be elucidated. Targeting
nociception with peripheral regional anaesthetic tech-
niques will have application for the treatment of acute
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postoperative pain. All three classical subtypes of opioid
receptors have been demonstrated in peripheral tissues
in afferent nerve terminals. Several clinical studies exist
that demonstrate peripheral opioid analgesia following
intraarticular opiate injection for knee surgery. A re-
viewer of this work concluded that morphine had a def-
inite but mild benefit lasting 24 hours, exceeding any
expected systemic effect. Clinical studies also exist on
the effect of opioids injected perineurally (4, 22). The
two aspects studied have been whether there is a statisti-
cally significant benefit of perineural opioid on sen-
sorimotor block (intraoperative anaesthesia) or analge-
sia (postoperative) and also its extent and duration. The
evidence so far has been inconclusive because of study
design. With few exceptions, the studies were not done
in such a way as to exclude a systemic opioid effect or
central spread of the injected opioid to receptors on the
dorsal root ganglia or the neuraxis. Another design
weakness was that the systemic morphine control pa-
tients received an IV bolus, though an IM injection
might more closely mirror or exclude a systemic effect
of a perineural morphine injection.
Tramadol
The central and peripheral analgesic effects of trama-
dol have not been fully explained but it is a selective ago-
nist of m-receptors, many times weaker than morphine.
Tramadol also prevents reuptake of noradrenaline and
enhances both serotonin and noradrenaline release. The
monoaminergic activity of tramadol increases the inhibi-
tory activity of the descending pain pathways, resulting
in a suppression of nociceptive transmission at the spinal
level.
Only few studies have investigated the effect of trama-
dol added to peripheral plexus blockade, but the conclu-
sion was that the addition of 100 mg tramadol to brachial
plexus anaesthesia prolongs the duration of the sensory
and motor block significantly. In one study there was a
control group receiving the same amount of tramadol IV
to exclude a central effect as a result of systemic absorp-
tion. With the potential for doses of tramadol other than
100 mg to provide analgesia, Robaux designed a double-
blind RCT to study the dose-effect relationship and de-
termine the optimal dose of tramadol added to brachial
plexus anaesthesia for carpal tunnel release surgery (25).
All 100 patients received 1.5% mepivacaine 40 mL plus a
study solution containing either isotonic sodium chlo-
ride or tramadol (40 mg, 100 mg, 200 mg). This study
suggests that tramadol added to 1.5% mepivacaine for
brachial plexus block enhances in a dose-dependent man-
ner the duration of analgesia with acceptable side effects.
However, the authors pointed out that the safety of tra-
madol has to be investigated before allowing its use in
clinical practice.
The results of a prospective, randomized, double-
blind study by Kesimci demonstrated that the addition of
100 mg of tramadol to ropivacaine for axillary brachial
plexus block did not improve the speed of onset of block
or increase the duration of sensory or motor block or
post-operative analgesia (26). The lack of analgesic effect
could be related to the choice of a long-acting local an-
aesthetic (ropivacaine) at a dose (40 ml, 7.5 mg/ml) that
provides a long duration of analgesia, which could have
masked any potential peripheral analgesic effect of tra-
madol 100 mg on the nerve block. Kaabachi studied 102
patients scheduled for hand surgery under axillary block
with lidocaine 1.5% (epinephrine 1/200,000) and the ad-
dition of either saline or tramadol (100 mg, 200 mg) (27).
The authors report that 200 mg tramadol prolonged both
intraoperative blocks and postoperative analgesia in this
setting. However, a high dose of tramadol (200 mg) was
also associated with a delayed onset of anaesthesia. In an-
other dose-ranging study, 200 mg tramadol added to
mepivacaine 1.5% in axillary block prolonged only dura-
tion of postoperative analgesia and did not increase the
onset time of anaesthesia. The discrepancy between these
findings and those of Robaux et al. may be related to sev-
eral differences in the study design, such as nerve stimu-
lation technique, definitions of the onset time, the qual-
ity of sensory block and the surgical procedures as such
(25).
The currently available data concerning the use of
opioids (including tramadol) as adjuvants for plexus or
peripheral blocks are limited and further studies of high




It has been assumed that epinephrine’s primary me-
chanism of action is to reduce drug clearance from the
epidural space via local vasoconstriction. Decreased clea-
rance is not the only possible explanation for the lower
local anaesthetic peak plasma concentrations. This could
also result from an epinephrine-induced increase in clea-
rance from plasma or an increase in volume of distribu-
tion. Because systemic absorption of epinephrine from
the epidural space produces a significant increase in car-
diac output it is not unreasonable to expect that plasma
clearance may be increased because of more rapid drug
delivery to the liver or kidneys. In a recent study by
Bernards, however, an equivalent dose of intramuscular
epinephrine had no effect on the plasma pharmacokine-
tics of any of the study drugs (28).
Because the effects of epinephrine on blood flow are
concentration dependent, one would expect epinephrine
to reduce blood flow in tissues in which it was present at
high concentrations (vasoconstriction) and increase flow
in tissues in which it was present at low concentrations
(vasodilatation). It is also important not to draw direct
comparisons between the behaviour of local anaesthetics
and opioids in the epidural space, because local anaes-
thetics, unlike opioids, can themselves increase local blood
flow and thereby increase their own elimination. This
ability may explain why the effects of epinephrine on local
anaesthetic pharmacokinetics are more dramatic then
those on opioids. After local anaesthetic infiltration into
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tissue, blood vessels dilate (procaine > prilocaine), re-
sulting in increased blood flow to the site, which can lead
to a higher rate of absorption of local anaesthetic into the
circulation. Some local anaesthetics, on the other hand,
demonstrate vasoconstriction in clinical use (cocaine,
mepivacaine, ropivacaine). The addition of a vasocon-
strictor (e.g. epinephrine) may further decrease the plas-
ma concentration of these local anaesthetics, permitting
use of higher doses of local anaesthetic.
The effect on duration of local anaesthetic action is
variable, based on the agent used. Local anaesthetics
with shorter durations of effect (lidocaine and procaine)
demonstrate a greater degree of prolongation with the
addition of 1:200,000 epinephrine compared with lon-
ger-acting anaesthetics (eg, ropivacaine). Addition of
epinephrine has also been shown to increase the speed of
onset of a regional block, along with increasing the depth
of block.
Förster studied whether epinephrine 4 µg/mL im-
proves the efficacy of ropivacaine-fentanyl lumbar epi-
dural analgesia (LEA) after total knee arthroplasty (29).
As part of the multimodal pain treatment used, the epi-
dural adjuvant epinephrine (12–32 µg/h) did not improve
LEA after total knee arthroplasty. The present findings
contrast studies in which epinephrine as an adjuvant to
thoracic epidural analgesia has proven beneficial.
Another aspect is that hydrophilic drugs are cleared
from the epidural space by a different route than are very
lipid-soluble drugs and that epinephrine affects clear-
ance from these sites differently. If epinephrine affects
epidural fat blood flow differently from dura blood flow,
then one would expect epinephrine to affect the clear-
ance of drugs that partition preferentially into epidural
fat differently from drugs that do not. Epinephrine may
not attain high enough concentrations in epidural fat to
produce vasoconstriction. Instead, because of its hydro-
philicity, epinephrine might be present in such relatively
low concentrations in the epidural fat that it causes vaso-
dilatation through a2-adrenergic receptors.
Not to forget is the fact that epinephrine itself is anal-
gesic in the spinal cord via its activation of a2-adrenergic
receptors.
Clonidine
The central a2-adrenergic agonist clonidine also in-
hibits nociceptive impulses by activating postjunctional
a2-adrenoceptors in the dorsal horn of the spinal cord.
This kind of receptors are located on primary afferent
terminals (both at peripheral and spinal endings), on
neurons in the superficial laminae of the spinal cord and
within several brainstem nuclei implicated in analgesia.
Clonidine enhances and prolongs sensory and enhances
motor blockade from local anaesthetic used for epidural
or peripheral nerve block (25). A postulated mechanism
for this is that clonidine blocks conduction of C and
A-delta fibres and increases potassium conductance in
isolated neurons in vitro, thus intensifying conduction
block. Secondly, clonidine causes local vasoconstriction
in the clinical setting, thereby reducing vascular uptake
of local anaesthetic from around the neural structures.
The a2-adrenergic agonists also enhance analgesia from
intraspinal opioids by interactions both pre- and post-
synaptically within the spinal cord. Neuraxial adminis-
tration of clonidine also has a local effect on sympathetic
nerves in the spinal cord. The clinical use of intrathecal
clonidine is hampered by the side effects of sedation,
bradycardia, and hypotension; whereas up to 150 µg of
clonidine added to plexus blocks would prolong analge-
sia without increasing side effects.
An experimental study by Wollf was designed to in-
vestigate the local anaesthetic-like action of clonidine in
superficial dorsal horn neurones (32). The superficial
laminae contain important structures for pain transmis-
sion, receiving most of their primary sensory input from
Ad and C fibres. It was shown that clonidine suppresses
the generation of action potentials in tonic-firing spinal
dorsal horn neurones, and that clonidine therefore could
contribute to analgesia during local anaesthesia.
Dobrydnjov performed a double-blinded RCT of an-
algesia in patients having clonidine added to local anaes-
thetic during combined spinal-epidural anaesthesia for
hip arthroplasty. Low-dose intrathecal clonidine provid-
ed a better quality of anaesthesia and longer-lasting anal-
gesia (33). Epidural clonidine-ropivacaine infusion re-
sulted in improved postoperative analgesia but was associ-
ated with a moderate decrease in blood pressure. Also the
addition of intrathecal clonidine 15 µg to bupivacaine
during combined spinal-epidural anaesthesia provided a
higher quality of anaesthesia and longer lasting analge-
sia than bupivacaine alone. More dose-finding studies
are needed in order to find the most effective dose in rela-
tion to side effects.
In a study by Kaabachi clonidine 1 µg/kg was used as
an adjuvant to plain bupivacaine for spinal anaesthesia
in adolescents. The addition of clonidine prolonged the
duration of sensory block achieved with bupivacaine by
30 min and postoperative analgesia by 120 min without
severe adverse events (34).
Bhatnagar et al. evaluated the effect of clonidine as an
adjuvant to bupivacaine for continuous paravertebral
nerve block. The authors concluded that using clonidine
as an adjunct improves pain relief after thoracotomy, but
hypotension and sedation are adverse effects interfering
with its clinical application. The study did not rule out
that systemically absorbed clonidine may have contrib-
uted to this (35).
There is little knowledge of the pharmacokinetics of
local anaesthetics and adjunctive analgesics after para-
vertebral blockade. Pharmacokinetic data may help dis-
tinguish between a local or systemic site of action. Burlacu
evaluated the pharmacokinetics of low-dose levobupi-
vacaine, fentanyl, and clonidine after paravertebral anal-
gesia for breast surgery (24). In this study, patients re-
ceived opioid-free general anaesthesia and postoperative
clonidine patient-controlled analgesia. In conclusion, after
paravertebral bolus and infusion administration fentanyl
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and clonidine in paravertebral block results in Cpmax
concentrations less than the effective levels for these drugs
when systemically administered. This would suggest but
not prove that their mechanism of action is at least partly
attributable to a local effect.
Kaabachi studied 98 children, scheduled for elective
outpatient herniorrhaphy or orchidopexy, that were ran-
domly allocated to receive an ilioinguinal–iliohypogastric
bupivacaine nerve block either with or without 1µg/kg
clonidine (30). The study failed to demonstrate any ad-
vantage of adding clonidine to bupivacaine for ilioingui-
nal-iliohypogastric nerve block.
In axillary plexus block, some studies have shown that
clonidine prolongs the local anaesthetic block whereas
other trials found contrasting results (36). Duma et al.
therefore studied clonidine as an adjuvant to local anaes-
thetic in axillary brachial plexus block. The results
showed no significant difference in onset of motor or
sensory block when plain local anaesthetic was com-
pared with anaesthetic plus clonidine in axillary brachial
plexus. With regard to prolongation of block, it is inter-
esting to note that clonidine is recommended by many to
prolong duration of axillary plexus block.
In a qualitative systematic review of the literature by
McCartney the question was asked whether we should
add clonidine to local anaesthetic for peripheral nerve
blockade (37). Of the 27 studies reviewed, only 5 studies
included a systemic control group. The total number of
patients reviewed was 1,385. The dose of clonidine var-
ied from 30 to 300 µg. Overall 15 studies supported the
use of clonidine as an adjunct to peripheral nerve blocks
with 12 studies failing to show a benefit. Based on quali-
tative analysis, clonidine appeared to prolong analgesia
when added to intermediate-acting local anaesthetics
(such as mepivacaine and lidocaine) for some peripheral
nerve blocks (single shot axillary and peribulbar nerve
blocks). Side-effects appear to be limited at doses up to
150 µg. It was also concluded that evidence is lacking for
the use of clonidine as an adjunct to local anaesthetics for
continuous catheter techniques, and that further re-
search is required to examine the peripheral analgesic
mechanism of clonidine. Despite some evidence for
clonidine as an adjunct in other upper and lower limb
blocks too few studies are available to make definitive
conclusions.
The inclusion of a systemic control group is impor-
tant in determining if clonidine has a peripheral or a sys-
temic effect. Five studies in the review included a sys-
temic control to investigate if clonidine had a local as
opposed to systemic effect. Three studies were supportive
of a purely peripheral analgesic effect of clonidine and
two were negative.
Huang studied dose–response of epidural clonidine
for postoperative pain after total knee arthroplasty
(TKA) (38). The main finding of this randomized study
was that the optimal epidural clonidine concentration in
a morphine and ropivacaine solution after TKA was 1.0
µg/mL. This combination resulted in excellent pain re-
lief during the 72 h period after surgery and was not
accompanied by significant hypotension or sedation.
Motor and sensory blockade effects of local anaesthetics
were enhanced by clonidine, and effects on the prolonga-
tion of sensory nerve blockade were clearly dose-depend-
ent. However, an earlier study has demonstrated that ad-
dition of clonidine to local anaesthetic for continuous
femoral nerve blockade can delay the recovery of motor
function as well.
In a systematic review of randomized trials, Elia stud-
ied clonidine as an adjuvant to intrathecal local anaes-
thetics for surgery. In conclusion, adding clonidine to
intrathecal local anaesthetics for surgery increases the
duration of the motor block, improves intraoperative an-
algesia, and delays the regression of the sensory block
and the time to first analgesic request. For some of the re-
ported effects, there is evidence of dose-responsiveness,
for others, there is not. None of these outcomes are likely
to last longer than 2 hours, why the clinical relevance will
be depending on the context. The most prominent ad-
verse effect is intraoperative hypotension (31).
NMDA antagonists
L-glutamate is perhaps the most important excitatory
neurotransmitter in the central nervous system. Blocking
the NMDA subtype of glutamate receptor offers an at-
tractive method of reducing afferent stimulation of the
spinal cord and therefore blocking pain transmission.
The primary reason for the restricted use of NMDA an-
tagonists as postoperative analgesics is that at efficacious
doses they can produce cerebral side-effects such as hal-
lucinations. Magnesium ion was first identified as an in-
hibitor of NMDA receptors in the spinal cord. Ketamine
produces central antinociception through the same
mechanism, but may also enhance analgesia through
various other mechanisms, such as interaction with spi-
nal opioid receptors, a2-adrenoreceptors, cholinergic and
serotonergic system. Large doses of ketamine given in-
trathecally may have neurotoxic potential in humans.
Epidural preservative-free ketamine, added to opioid-
-based epidural analgesia, can improve pain relief with-
out increasing side effects.
The admixture of magnesium to prilocaine for
axillary brachial plexus block provided a pronounced
prolongation of sensory and motor block without side ef-
fects as studied by Gunduz (39). Magnesium has shown
antinociceptive effects in both animal and human pain
models. These effects are primarily based on the regula-
tion of calcium influx into the cell and antagonism of the
N-methyl-D-aspartate receptor. A significant difference
in duration of sensory block occurred between the
100-mg and 150-mg perineural magnesium groups.
In a study by Turan it was concluded that the addition
of magnesium to lidocaine in IVRA demonstrated de-
creased intraoperative fentanyl consumption and pain
associated with the tourniquet (40). It also shortened
sensory and motor block onset times, prolonged sensory
and motor block recovery times, and improved the qual-
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ity of anaesthesia while prolonging the time to the first
postoperative analgesic requirement. The side effect
seen with magnesium is injection pain. The authors
claimed that the addition of magnesium to a local anaes-
thetic in IVRA is effective, but they also stressed the im-
portance of performing further studies before recom-
mending its routine use.
The efficacy of magnesium sulphate as an adjuvant to
lidocaine for intravenous regional anaesthesia for upper
limb surgery was evaluated by Narang in a prospective,
randomised and double-blinded study (41). It was
shown that adding the adjuvant hastened the onset of
sensory and motor block and decreased tourniquet pain
as judged by improved VAS scores and increased dura-
tion to the need for additional analgesia. No serious
side-effects were caused but transient pain on injection
of magnesium sulphate was common.
Midazolam
Intrathecal midazolam causes spinally mediated (seg-
mental) analgesia by binding to the benzodiazepine re-
ceptors that form part of a typical benzodiazepine GABA
receptor complex in the dorsal horn of spinal cord.
Adding intrathecal (preservative-free) midazolam may
potentiate the antinociceptive effect of morphine-like
agents by acting as a direct agonist at kappa and delta
opioid receptor sites in the spinal cord. A significant syn-
ergistic effect was shown experimentally after intrathecal
injection of a combination of midazolam and clonidine.
In earlier studies the potentiating of the analgesic effect
sought for, after intrathecal addition of midazolam to
bupivacaine, may be have been masked by clonidine. A
study by Boussofara evaluated the postoperative analge-
sic effect of adding midazolam to an intrathecal bupi-
vacaine-clonidine mixture. Potentiating of pain relief
with no change in duration of the motor blockade has
also been reported after adding intrathecal midazolam to
bupivacaine (42).
The use of intrathecal midazolam to improve peri-
operative analgesia was reviewed by Ho in a meta-analy-
sis of 13 RCT’s (43). Based on the limited data available,
intrathecal midazolam appears to improve perioperative
analgesia and reduce nausea and vomiting during cae-
sarean delivery. For other applications of using midazo-
lam in neuaraxial anaesthesia, a multicentre registry or
large randomised controlled study would be useful to
confirm the clinical safety of intrathecal administration.
Glucocorticoids
Acute inflammation from tissue injury has an impor-
tant role in the formation of surgical pain, and
glucocorticoids may be useful for its anti-inflammatory
effect. Studies using dexamethasone for postoperative
pain relief have produced positive results mainly in sur-
gery involving large amounts of tissue trauma. When
added to solutions for intravenous regional nerve blocks,
dexamethasone has been demonstrated to reduce pain
for the first 24 h after hand surgery. Bigat investigated the
anaesthetic and analgesic effectiveness of adding dexa-
methasone to lidocaine for intravenous regional anaes-
thesia (IVRA) in 75 patients undergoing ambulatory
hand surgery, and found a dose of 8 mg dexamethasone
effective when added to lidocaine (44). Although there
was prolonged sensory and motor blockade, time to re-
quest for first analgesic was significantly shorter in the
dexamethasone group but the total analgesic require-
ment for the first 24 hours was less in this group. In a
study by Movafegh, the same dose of 8 mg dexametha-
sone was added to lidocaine in order to prolong axillary
brachial plexus blockade. Sixty patients were included in
the study and the addition of glucocorticoid resulted in a
significant increase in duration of sensory and motor




NSAIDs inhibit the production of prostaglandins
from arachidonic acid in phospholipid membranes. The
result is decreased afferent nociceptive signals arising
from the site of surgery. Clinical studies have demon-
strated an enhanced analgesic effect from NSAIDs when
concentrated at a peripheral site compared to the sys-
temic administration of the same drug. This would sug-
gest a predominantly peripheral site of action. Concen-
trating the dose of NSAID at the site of surgery, either as
part of IVRA or wound infiltration, could result in longer
lasting analgesia than for the same dose administered
parenterally. This has not been sufficiently studied but
reports are available on the epidural injection of indo-
methacin and intraarticular administration of ketorolac
and tenoxicam. However, these studies suffer from the
lack of placebo groups or systemic controls.
Neostigmine
Intrathecal administration of the cholinesterase in-
hibitor neostigmine has been shown to produce analge-
sia, but also to cause adverse effect of motor block, dizzi-
ness, bradycardia, nausea or vomiting. The improved
analgesia results from an increase in concentration of
acetylcholine and consequent action at muscarinic and
presynaptic nicotinic receptors, stimulation of the pro-
duction of nitric oxide, release of gamma-aminobutyric
acid, in the cholinergic interneurons of the dorsal horn of
the spinal cord in proximity of opioid and adrenergic sites.
Hence combining cholinergic and alpha adrenergic agents
can be expected to enhance analgesia with side effects re-
lated solely to the dose of the individual drug. Neo-
stigmine involved in epidural anaesthesia, intravenous
regional anaesthesia or intraarticular injections short-
ened block onset times, prolonged sensory and motor
block, and prolonged time to first postoperative rescue
analgesic. Currently, however, data are insufficient to al-
low recommendations on the addition of neostigmine in
regional anaesthesia.
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